Pay in 4 interest-free payments of $6.25 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Martin Ars, president of Apotex Canada and Rest of World, said its version of semaglutide is expected to be on pharmacy shelves within the next few weeks
If you experience symptoms of the following adverse effects, stop taking semaglutide and contact your healthcare provider: Thyroid tumors: Semaglutide may increase the risk for certain types of thyroid tumors including medullary thyroid cancer or multiple endocrine neoplasia syndrome 2 (MEN2)
The Lancet, 397 (10278), 971984
Semaglutide marketed by Novo Nordisk under NDC Code 0169-4136-11 NDC Code(s) : 0169-4136-11, 0169-4136-02, 0169-4132-90, 0169-4132-97, 0169-4132-11, 0169-4132-12, 0169-4130-01, 0169-4130-13, 0169-4772-11, 0169-4772-12, 0169-4772-90, 0169-4772-97, 0169-4181-03, 0169-4181-13, 0169-4181-90, 0169-4181-97 Packager : Novo Nordisk Category : HUMAN PRESCRIPTION DRUG LABEL DEA Schedule : none Marketing Status : New Drug Application INGREDIENTS AND APPEARANCE LABELER - Novo Nordisk(622920320) PRINCIPAL DISPLAY PANEL 0.25 mg 0.5 mg NDC 0169-4181-13List 418113 OZEMPIC (semaglutide) injection For Single Patient Use Only 2 mg/3 mL (0.68 mg/mL) Prefilled pen Pen delivers doses in 0.25 mg or 0.5 mg increments only For subcutaneous use only Use OZEMPIC once weekly Contains: 1 OZEMPIC pen, 6 NovoFine Plus 32G needles, Product Literature
